Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 6, 2012, Pages 855-860

  Bernstein Molho, Rinat ^a   Kollender, Yehuda ^b   Issakov, Josephine ^b   Bickels, Jacob ^b   Dadia, Shlomo ^b   Flusser, Gideon ^b   Meller, Isaac ^b   Sagi Eisenberg, Ronit ^b   Merimsky, Ofer ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chondrosarcoma; Cyclophosphamide; mTOR; Sirolimus

Indexed keywords

CYCLOPHOSPHAMIDE; RAPAMYCIN;

ADULT; ANEMIA; ARTICLE; ASTHENIA; BLADDER CARCINOMA; BLOOD TOXICITY; CHONDROSARCOMA; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATURIA; HUMAN; HYPERGLYCEMIA; INOPERABLE CANCER; ISRAEL; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT FAILURE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHONDROSARCOMA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84871207566     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1968-x     Document Type: Article

References (25)

1. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE (2009) The clinical management of chondrosarcoma. Curr Treat Options Oncol 10(1-2):94-106
2. Jamil N, Howie S, Salter DM (2010) Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol 91(5):387-393
3. National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology. Bone cancer. National Comprehensive Cancer Network, Fort Washington, PA. Available at: http://www.nccn.org/professionals/physician-gls/ pdf/bone.pdf
4. Schuetze SM, Baker LH, Maki RG (2006) Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. In: J Clin Oncol. ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement), p 9503
5. Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R (2008) Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs 19(10):1019-1021
6. Wu MH, Lo JF, Kuo CH, Lin JA, Lin YM, Chen LM, Tsai FJ, Tsai CH, Huang CY, Tang CH (2012) Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. J Cell Physiol 227(8):3016-3026
7. Galoian K, Temple TH, Galoyan A (2011) Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem Res 36(5): 812-818
8. National Cancer Institute (2003) The NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. National Cancer Institute, Bethesda, MD. Available at: http://ctep.cancer. gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92(3):205-216
10. Gentzler RD, Altman JK, Platanias LC (2012) An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets. [Epub ahead of print]
11. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2):S43- S51
12. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4):257-262
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al (2007) Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 356(22):2271-2281
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
15. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523
16. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005-2012
17. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L et al (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30(1):78-84
18. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN (2011) A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 117(15): 3468-3475
19. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA et al (2010) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9(1):101-112
20. Mir O, Domont J, CioffiA, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A (2011) Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer 47(4):515-519
21. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98(10):2251-2256
22. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS (2005) Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 14(6):466-479
23. Burton JH, Mitchell L, Thamm DH, Dow SW, Biller BJ (2011) Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet Intern Med 25(4):920-926
24. Schuetze SM, Zhao L, Chugh R, Thomas DG, Lucas DR, Metko G, Zalupski MM, Baker LH (2012) Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 48(9):1347-1353
25. Cousin S, Taieb S, Penel N (2012) A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Curr Opin Oncol 24(3):338-344